International Study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE)

Nosocomial Pneumonia Clinical Trial

— PneumoINSPIRE  

Official title:

International, Multi Centre, Prospective, Observational Cohort Study of Nosocomial Pneumonia in Intensive Care Units

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02793141
• Other study ID #: 2015000302
• Status: Completed
• Start date: February 1, 2016
• Est. completion date: February 23, 2021

Study information

• Verified date: April 2021
• Source: The University of Queensland
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The International study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE) is a prospective, international, multicentre, observational, cohort study. The study aims to provide up-to-date and generalisable information on current worldwide epidemiology and clinical practice associated with diagnosis and management of nosocomial pneumonia in Intensive Care Unit (ICU) patients.

PneumoINSPIRE study is endorsed by the European Society of Intensive Care Medicine (ESICM).

Description:

Specifically, the study aims to:

• Evaluate the global epidemiology of nosocomial pneumonia in ICU patients, analysing responsible pathogens and resistance pattern by type of pneumonia and geographical region.

• Describe on a global scale current clinical practice regarding diagnosis and determine the degree of concordance between the diagnosis of nosocomial pneumonia in routine clinical practice and the official definitions including: a) ATS/IDSA 2005 guidelines; b) CDC/NHSN Surveillance Definitions (version January 2015, modified April 2015).

• Identify on a global scale variable treatment decisions with emphasis on therapeutic schemas, appropriateness, de-escalation decisions and their relation to outcomes.

Secondary objectives include:

• Evaluate nosocomial pneumonia in specific subgroups of critically ill patients (such as, chronic obstructive pulmonary disease [COPD], the elderly, postoperative, trauma patients).

• Describe the differences between nosocomial pneumonia in non-intubated ICU patients and VAP.

• Compare the characteristics and outcomes between patients with nosocomial pneumonia in ward patients later transferred to the ICU and non-intubated ICU patients with nosocomial pneumonia.

This international study will explore clinical details for nosocomial pneumonia in the ICU setting: practice variations among countries and continents, diagnostic and treatment modalities, implicated pathogens and their resistance patterns, resolution patterns and risk factors for unfavourable outcomes. In view of these, this global multicentre study shall provide useful information for the elaboration of future recommendations on diagnostic and treatment approaches for nosocomial pneumonia in the ICU.

Inclusion criteria:

ICU patients with a diagnosis of nosocomial pneumonia, including:

• Admission to the ICU with diagnosis of HAP that developed in the ward in non-intubated patients (Ward HAP)

• The first episode of ICU-acquired pneumonia that developed in non-intubated patients (ICU-HAP)

• The first episode of ICU-acquired pneumonia that developed in patients receiving invasive ventilation(i.e. Ventilator-Associated Pneumonia (VAP)).

Exclusion criteria:

• Age < 18 years

• Patients with nosocomial pneumonia receiving palliative treatment at the time of assessment for eligibility (i.e. the time of clinical diagnosis)

• Previous inclusion in the study

Research sites:

More than 150 ICUs from 25 or more countries worldwide that will agree to participate in the study.

Sample size:

A minimum of 10 consecutive ICU patients with nosocomial pneumonia as described above will be recruited per site. A sample size of at least 1000 ICU patients with nosocomial pneumonia is anticipated to comprise the dataset. This sample size has been chosen to provide generalisable data for each geographic region and to satisfy power considerations.

Statistical analysis:

Descriptive analytic, techniques and parametric and non-parametric tests will be used to explore diagnostic, microbiological or subgroup differences as well as clinical outcomes of nosocomial pneumonia. Cox regression will be used to predict dichotomous outcomes of interest, including mortality and pneumonia resolution. Independent predictors and associated hazard ratios with 95% confidence intervals will be reported. A two-sided p-value less than 0.05 will be considered statistically significant.

Proposed Start and End Date:

The first site is anticipated to commence recruitment in March 2016 with staggered site recruitment; however, sites are anticipated to start recruitment during the first half of 2016; each site will commence recruitment as soon as relevant Institutional Review Board approvals have been obtained. Recruitment will continue until the minimum target of 10 patients has been reached. Sites will have the opportunity for further recruitment while the study is active. Completion of recruitment is anticipated to occur by end December 2018.

Dissemination of Findings:

Summary data will be presented in a timely manner at national and international conferences and in peer-reviewed journals.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1657
• Est. completion date: February 23, 2021
• Est. primary completion date: February 23, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

ICU patients with a diagnosis of nosocomial pneumonia, including:

• Admission to the ICU with diagnosis of HAP that developed in the ward in non-intubated patients (Ward HAP)

• The first episode of ICU-acquired pneumonia that developed in non-intubated patients

• The first episode of ICU-acquired pneumonia that developed in patients receiving invasive ventilation (i.e. Ventilator-Associated Pneumonia (VAP)).

Exclusion Criteria:

• Age < 18 years

• Patients with nosocomial pneumonia receiving palliative treatment at the time of assessment for eligibility

• Previous inclusion in the study

Related Conditions & MeSH terms

• Healthcare-Associated Pneumonia
• Nosocomial Pneumonia
• Pneumonia

Intervention

Other:
• No intervention
No intervention will be administered

Locations

Country	Name	City	State
Australia	Royal Brisbane and Womens Hospital (RBWH)	Brisbane
Greece	University Critical Care Department, Aghioi Anargyroi Hospital	Athens	Attica

Sponsors (2)

Lead Sponsor	Collaborator
The University of Queensland	European Society of Intensive Care Medicine

Countries where clinical trial is conducted

Australia,  Greece, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	ICU and hospital mortality, censored at Day 28 if ICU discharge is later than day 28. Day 1 is the day of onset for pneumonia with arises in the ICU and day of ICU admission for pneumonia without ICU onset.	Day 28
Primary	Degree of concordance of clinical diagnosis of VAP with official definitions	The degree of concordance with diagnosing nosocomial pneumonia with: ATS/IDSA 2005 Guidelines; CDC/NHSN Surveillance definitions (Jan 2015, modified April 2015)	Day 28 or ICU discharge, whichever occurs first
Primary	Pathogenic organism (categorical)	Responsible pathogens and resistance pattern by type of pneumonia and geographical region (% per category)	Day 28 or ICU discharge, whichever occurs first
Primary	Clinical management of pneumonia (categorical)	Empirical management, modification of empirical management (escalation, de-escalation and discontinuation) and duration of antibiotic treatment for pneumonia	Day 28 or ICU discharge, whichever occurs first
Primary	Resolution of pneumonia (categorical)	Clinical resolution of the pneumonia at pre-selected time periods	Day 3, 7 and 14
Secondary	Recurrence of pneumonia	Clinical recurrence of the pneumonia within a set period of time	Day 14 and 28
Secondary	Mechanical ventilation-free days	Number of days the patient does not require mechanical ventilation whilst in ICU and censored at Day 28	Censored at Day 28 or discharge from ICU, whichever occurs first
Secondary	Number of antibiotic-free days	Number of days patient did not require antibiotic therapy whilst in ICU and censored at Day 28	Censored at Day 28 or discharge from ICU, whichever occurs first